Report on in vivo efficacy of the reprogramming

Inject Rpf-GSCs stereotactically in RNU rats. Quantify and spatially analyse the fluorescence. Animals bearing vascularised tumours (5-6/group) will receive ipsilaterally: (i) iR-NSCs (treatment group); (ii) PBS (-ve control); (iii) iNSC expressing TRAIL (+ve control). Image in vivo daily until regression or death. Perform histology for regression and target protein readouts ex vivo. Isolate and characterize EXs from iR-NSC organoids cultures, animal models (serum and urine) as in T1.2.